Dietary sphingomyelin alleviates experimental inflammatory bowel disease in mice

International Journal for Vitamin and Nutrition Research

Volumn 78, Issue 1, 2008, Pages 41-48

  Furuya, Hideki ^a   Ohkawara, Sou ^a   Nagashima, Kousuke ^a   Asanuma, Narito ^a   Hino, Tsuneo ^a,b  

^a MEIJI UNIVERSITY   (Japan)

^b NONE

Author keywords

Dextran sulfate sodium; IgA; Inflammatory bowel disease; Mice; Sphingomyelin

Indexed keywords

DEXTRAN; IMMUNOGLOBULIN A; MYELOPEROXIDASE; SODIUM SULFATE; SPHINGOMYELIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME ACTIVITY; IMMUNOGLOBULIN PRODUCTION; INFLAMMATION; MALE; MOUSE; NONHUMAN;

ANIMALS; BODY WEIGHT; DEXTRAN SULFATE; DIET; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN A; INFLAMMATORY BOWEL DISEASES; INTESTINE, LARGE; MALE; MICE; MICE, INBRED ICR; PEROXIDASE; SEVERITY OF ILLNESS INDEX; SPHINGOMYELINS; SPLEEN; TIME FACTORS; TREATMENT OUTCOME;

MUS;

EID: 48749099833     PISSN: 03009831     EISSN: None     Source Type: Journal    
DOI: 10.1024/0300-9831.78.1.41     Document Type: Article

References (48)

1. Hannun, Y.A. andLinardic, C.M. (1993) Sphingolipid breakdown products: anti-proliferative and tumor-suppressor lipids. Biochim. Biophys. Acta. 1154, 223-236.
2. Spiegel, S. and Merrill, A.H. Jr. (1996) Sphingolipid metabolism and cell growth regulation. FASEB J. 10, 1388-1397.
3. 3 in HL-60 cells. Role in cell differentiation. J. Biol. Chem. 264, 19076-19080.
4. Hannun, Y.A. (1994) The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem. 269, 3125-3128.
5. Kolesnick, R. and Golde, D.W. (1994) The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 77, 325-328.
6. Hannun, Y.A., Loomis, C.R., Merrill, A.H. Jr. and Bell, R.M. (1986) Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J. Biol. Chem. 261, 12604-12609.
7. Ballou, L.R., Laulederkind, S.J., Rosloniec, E.F. and Raghow, R. (1996) Ceramide signalling and the immune response. Biochim. Biophys. Acta 1301, 273-287.
8. Tokura, Y., Wakita, H., Yagi, H., Nishimura, K., Furukawa, F. and Takigawa, M. (1996) Th2 suppressor cells are more susceptible to sphingosine than Th1 cells in murine contact photosensitivity. J. Invest. Dermatol. 107, 34-40.
9. Vesper, H., Schmelz, E.M., Nikolova-Karakashian, M.N., Dillehay, D.L., Lynch, D.V. and Merrill, A.H. Jr. (1999) Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J. Nutr. 129, 1239-1250.
10. Dillehay, D.L., Webb, S.K., Schmelz, E.M. and Merrill, A.H. Jr. (1994) Dietary sphingomyelin inhibits 1,2-dimethylhy-drazine-induced colon cancer in CF1 mice. J. Nutr. 124, 615-620.
11. Lemonnier, L.A., Dillehay, D.L., Vespremi, M.J., Abrams, J., Brody, E. and Schmelz., E.M. (2003) Sphingomyelin in the suppression of colon tumors: prevention versus intervention. Arch. Biochem. Biophys. 419, 129-138.
12. Schmelz, E.M., Dillehay, D.L., Webb, S.K., Reiter, A., Adams, J. and Merrill, A.H. Jr. (1996) Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Cancer Res. 56, 4936-4941.
13. Schmelz E.M., Sullards, M.C., Dillehay, D.L. and Merrill, A.H. Jr. (2000) Colonic cell proliferation and aberrant crypt foci formation are inhibited by dairy glycosphingolipids in 1, 2-dimefhylhydrazine-treated CF1 mice. J. Nutr. 130, 522-527.
14. Ahn, E.H. and Schroeder, J.J. (2002) Sphingoid bases and ceramide induce apoptosis in HT-29 and HCT-116 human colon cancer cells. Exp. Biol. Med. 227, 345-353.
15. Nilsson, A. (1968) Metabolism of sphingomyelin in the intestinal tract of the rat. Biochim Biophys Acta 164, 575-584.
16. Schmelz, E.M., Crall, K.J., Larocque, R., Dillehay, D.L. and Merrill, A.H. Jr. (1994) Uptake and metabolism of sphingolipids in isolated intestinal loops of mice. J Nutr. 124, 702-712.
17. Fiocchi, C. (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115, 182-205.
18. Blumberg, R.S., Saubermann, L.J. and Strober, W. (1999) Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr. Opin. Immunol. 11, 648-656.
19. Logan, R.F. (1998) Inflammatory bowel disease incidence: up, down or unchanged? Gut 42, 309-311.
20. Jergens, A.E. (1999) Inflammatory bowel disease. Current perspectives. Vet. Clin. North Am. Small Anim. Pract. 29, 501-521.
21. Hino, T. and Asanuma, N. (2004) Impact of intestinal bacteria on the health of dogs and cats. J. Pet. Anim. Nutr. 7, 139-152.
22. Murch, S.H. and Walker-Smith, J.A. (1998) Nutrition in inflammatory bowel disease. Baillieres. Clin. Gastroenterol. 12, 719-738.
23. Itzkowitz, S.H. and Yio, X. (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G7-G17.
24. Levin, B. (1992) Inflammatory bowel disease and colon cancer. Cancer 70, 1313-1316.
25. Cheng, Y., Tauschel, H.D., Nilsson, A.and Duan, R.D.(1999) Ursodeoxycholic acid increases the activities of alkaline sphingomyelinase and caspase-3 in the rat colon. Scand. J. Gastroenterol. 34, 915-920.
26. Kaiser, G.C., Yan, F. and Polk, D.B. (1999) Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes, Gastroenterology 116, 602-609.
27. Duan, R. (2003) Potential link between sphingomyelin metabolism and colonic tumorigenesis. In: Exogenous Factors in Colonic Carcinogenesis. (Scheppach, W. and Scheurlen, M., eds.), pp. 142-153, Kluwer Academic Publishers, Lancaster, UK.
28. Earnest, D.L., Holubec, H., Wali, R.K., Jolley, C.S., Bissonette, M., Bhattacharyya, A. K., Roy, H., Khare, S. and Brasitus, T.A. (1994) Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid, Cancer Res. 54, 5071-5074.
29. Rubin, D.T. and Lashner, B.A. (2005) Will a 5-ASA a day keep the cancer (and dysplasia) away? Am. J. Gastroenterol. 100, 1354-1356.
30. Lim, B.O. (2004) Efficacy of wogonin in the production of immunoglobulins and cytokines by mesenteric lymph node lymphocytes in mouse colitis induced with dextran sulfate sodium. Biosci. Biotechnol. Biochem. 68, 2505-2511.
31. American Institute of Nutrition. (1977) Report of the American Institute of Nutrition ad hoc committee on standards for nutritional studies. J. Nutr. 107, 1340-1348.
32. American Institute of Nutrition. (1980) Second report of ad hoc committee on standards for nutritional studies. J. Nutr. 110, 1726.
33. Kabashima, K., Saji, T., Murata, T., Nagamachi, M., Matsuoka, T., Segi, E., Tsuboi, K., Sugimoto, Y., Kobayashi, T., Miyachi, Y., Ichikawa, A. and Narumiya, S. (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 109, 883-893.
34. Hartmann, G., Bidlingmaier, C., Siegmund, B., Albrich, S., Schulze, J., Tschoep, K., Eigler, A., Lehr, HA. and Endres, S. (2000) Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J. Pharmacol. Exp. Ther. 292, 22-30.
35. Cooper, H.S., Murthy, S.N.S., Shah, R.S. and Sedergran, D.J. (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69, 238-249.
36. Oda, T. (1995) Role of mast cells in dextran sulfate sodiuminduced experimental colitis in rats. J. Kyoto Pref. Univ. Med. 104, 1069-1082.
37. Tian, L., Huang, Y.X., Tian, M., Gao, W. and Chang, Q. (2003) Downregulation of electroacupuncture at ST36 on TNF-α in rats with ulcerative colitis. World J. Gastroenterol. 9, 1028-1033.
38. Jurjus, A.R., Khoury, N.N. and Reimund, J.M. (2004) Animal models of inflammatory bowel disease. J. Pharmacol. Toxicol. Methods 50, 81-92.
39. Tenikoff, D., Murphy, K.J., Le, M., Howe, P.R. and Howarth, G.S. (2005) Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease. J. Gastroenterol. 40, 361-365.
40. Krawisz, J.E., Sharon, P. and Stenson, W.F. (1984) Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87, 1344-1350.
41. Head, K.A. and Jurenka, J.S. (2003) Inflammatory bowel disease Part 1: ulcerative colitis - pathophysiology and conventional and alternative treatment options. Altern. Med. Rev. 8, 247-283.
42. Parlesak, A., Schafer, C. and Bode, C. (2002) IgA against gut-derived endotoxins: does it contribute to suppression of hepatic inflammation in alcohol-induced liver disease? Dig. Dis. Sci. 47, 760-766.
43. Murthy, A.K., Dubose, C.N., Banas, J.A., Coalson, J.J. and Arulanandam, B.P. (2006) Contribution of polymeric immunoglobulin receptor to regulation of intestinal inflammation in dextran sulfate sodium-induced colitis. J. Gastroenterol. Hepatol. 21, 1372-1380.
44. Sjoqvist, U., Hertervig, E., Nilsson, A., Duan, R. D., Ost, A., Tribukait, B. and Lofberg, R. (2002) Chronic colitis is associated with a reduction of mucosal alkaline sphingomyelinase activity. Inflamm. Bowel Dis. 8, 258-263.
45. Furuya, H., Ohkawara, S., Asanuma, N. and Hino, T. (2005) Application of sphingomyelin to the prevention of colorectal cancer in dogs, and utilization of intestinal bacteria to maximize the effect. J. Pet Anim. Nutr. 8, 30-39.
46. Duan, R.D. (2006) Alkaline sphingomyelinase: an old enzyme with novel implications. Biochim. Biophys. Acta 1761, 281-291.
47. Ballou, L.R., Chao, C.P., Holness, M.A., Barker, S.C. and Raghow, R. (1992) Interleukin-1 -mediated PGE2 production and sphingomyelin metabolism. Evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide. J. Biol. Chem. 267, 20044-20050.
48. Candela, M., Barker, S.C. and Ballou, L.R. (1991) Sphin-gosine synergistically stimulates tumor necrosis factor alpha-induced prostaglandin E2 production in human fibroblasts. J. Exp. Med. 174, 1363-1369.